Page 1 | Search Results | Blood | American Society of Hematology

1-17 of 17

Sort by

Sort Order Select

Journal Articles

Investigating Effects of Cyclosporine on Eltrombopag Pharmacokinetics in Healthy Volunteers: A Phase 1 Crossover, Drug-Drug Interaction Study

Jianping Zhang, PhD, Connie L. Erickson-Miller, PhD, Geoffrey Chan, MD, Yan Yan Zhou, PhD

Blood (2015) 126 (23): 4791.

https://doi.org/10.1182/blood.V126.23.4791.4791

Published: 2015

Journal Articles

Eltrombopag, but Not Romiplostim or Thrombopoietin, Inhibits Growth of Thrombopoietin Receptor Positive and Negative Human Leukemia Cell Lines

David W. Rusnak, Sharon K. Rudolph, Afshin Safavi, PhD, Connie L. Erickson-Miller, PhD

Blood (2012) 120 (21): 4726.

https://doi.org/10.1182/blood.V120.21.4726.4726

Published: 2012

Journal Articles

Hepatic HIF-2 regulates erythropoietic responses to hypoxia in renal anemia

Pinelopi P. Kapitsinou, Qingdu Liu, Travis L. Unger, Jennifer Rha, Olena Davidoff, Brian Keith, Jonathan A. Epstein, Sheri L. Moores, Connie L. Erickson-Miller, Volker H. Haase

Blood (2010) 116 (16): 3039–3048.

https://doi.org/10.1182/blood-2010-02-270322

Published: 2010

Includes: Supplemental data

Journal Articles

Eltrombopag Decreases Proliferation of Ovarian, Lung and Breast Tumor Cell Lines.

Connie L. Erickson-Miller, Jennifer Kirchner, Kodandaram Pillarisetti, Lone Ottesen, Yasser Mostafa Kamel, Yuan Liu, Anne-Marie Martin, Conrad Messam

Blood (2009) 114 (22): 2409.

https://doi.org/10.1182/blood.V114.22.2409.2409

Published: 2009

Journal Articles

In-Vitro Effect of the Small Molecule Thrombopoietin (TPO) Receptor Agonist Eltrombopag in Chronic Lymphocytic Leukemia (CLL).

Thorsten Zenz, Antonio Sarno, Andrea Schnaiter, Dirk Winkler, Andreas Bühler, Matthias Volden, Connie L. Erickson-Miller, Yasser Mostafa Kamel, Hartmut Döhner, Stephan Stilgenbauer

Blood (2009) 114 (22): 4408.

https://doi.org/10.1182/blood.V114.22.4408.4408

Published: 2009

Journal Articles

Effect of the nonpeptide thrombopoietin receptor agonist Eltrombopag on bone marrow cells from patients with acute myeloid leukemia and myelodysplastic syndrome

Britta Will, Masahiro Kawahara, Julia P. Luciano, Ingmar Bruns, Samir Parekh, Connie L. Erickson-Miller, Manuel A. Aivado, Amit Verma, Ulrich Steidl

Blood (2009) 114 (18): 3899–3908.

https://doi.org/10.1182/blood-2009-04-219493

Published: 2009

Journal Articles

Low or Undetectable Levels of Thrombopoietin Receptor (Tpo-R; c-mpl) Expression on Tumor Cell Lines and Primary Tumors Compared with Epo-R, ErbB2, and IGF-1R

Connie L Erickson-Miller, Antony Chadderton, Anna Gibbard, Jennifer Kirchner, Lone Ottesen, Katherine Baker, Lini Pandite, Iman El-Hariry, Yasser Mostafa Kamel, Yuan Liu, Anne-Marie Martin, Conrad Messam

Blood (2008) 112 (11): 5394.

https://doi.org/10.1182/blood.V112.11.5394.5394

Published: 2008

Journal Articles

DYRK3 Encodes an Inhibitor of Erythroid Differentiation and Is Expressed at High Levels in Patients with Anemia.

David P. Steensma, MD, Julie C. Porcher, BS, Antony Chadderton, MS, Kevin Laubscher, MS, Deb Jaworski, PhD, Joanne J. Lager, MD, William Bell, MS, JD, Bryan E. Hoffman, PhD, Connie L. Erickson-Miller, PhD

Blood (2007) 110 (11): 3661.

https://doi.org/10.1182/blood.V110.11.3661.3661

Published: 2007

Journal Articles

The Characterization of DYRK3 mRNA and the Utility of DYRK3 Inhibitors in a Carboplatin/Radiation Mouse Model of Anemia.

Connie L. Erickson-Miller, PhD, Ying Homan, BA, Matthew Chomo, BS, Elizabeth I. Valoret, MS, Louis Elefante, BA, Amy Landis, MS, Antony Chadderton, MS, Christopher B. Hopson, BA

Blood (2007) 110 (11): 2202.

https://doi.org/10.1182/blood.V110.11.2202.2202

Published: 2007

Journal Articles

GSK626616: A DYRK3 Inhibitor as a Potential New Therapy for the Treatment of Anemia.

Connie L. Erickson-Miller, PhD, Caretha Creasy, PhD, Antony Chadderton, MS, Christopher B. Hopson, BS, Elizabeth I. Valoret, MS, Michele Gorczyca, MS, Louis Elefante, BA, Don M. Wojchowski, PhD, Matthew Chomo, MS, Duke M. Fitch, PhD, Kevin J. Duffy, PhD

Blood (2007) 110 (11): 510.

https://doi.org/10.1182/blood.V110.11.510.510

Published: 2007

Journal Articles

Eltrombopag Decreases Proliferation of Human Leukemia and Lymphoma Cell Lines In Vitro.

Connie L. Erickson-Miller, PhD, Parrish L. Payne, Sherri Moore, Sherryann Wert, Richard D. May

Blood (2007) 110 (11): 4089.

https://doi.org/10.1182/blood.V110.11.4089.4089

Published: 2007

Journal Articles

Phase 1 clinical study of eltrombopag, an oral, nonpeptide thrombopoietin receptor agonist

Julian M. Jenkins, Daphne Williams, Yanli Deng, Joanne Uhl, Valerie Kitchen, David Collins, Connie L. Erickson-Miller

Blood (2007) 109 (11): 4739–4741.

https://doi.org/10.1182/blood-2006-11-057968

Published: 2007

Journal Articles

Species Specificity and Receptor Domain Interaction of a Small Molecule TPO Receptor Agonist.

Connie L. Erickson-Miller, PhD, Evelyn Delorme, PHD, Maya Iskander, Leslie Giampa, Christpher B. Hopson, Juan Luengo, PhD, Kevin Duffy, PhD, Susan B. Dillon, PhD, Jon Rosen, PhD, Stephen Miller, PhD, Peter Lamb, PhD, Shin-Shay Tian, PhD

Blood (2004) 104 (11): 2909.

https://doi.org/10.1182/blood.V104.11.2909.2909

Published: 2004

Journal Articles

Discovery of SB-497115, a Small-Molecule Thrombopoietin (TPO) Receptor Agonist for the Treatment of Thrombocytopenia.

Juan I. Luengo, Kevin J. Duffy, Anthony N. Shaw, Evelyne Delorme, Kenneth J. Wiggall, Leslie Giampa, Nannan Liu, Heather Smith, Shin-Shay Tian, Stephen G. Miller, Richard M. Keenan, Jon Rosen, Susan B. Dillon, Peter Lamb, Connie L. Erickson-Miller

Blood (2004) 104 (11): 2910.

https://doi.org/10.1182/blood.V104.11.2910.2910

Published: 2004

Journal Articles

Effects of SB559457, a Novel Small Molecule Thrombopoietin Receptor (TpoR) Agonist, on Human Hematopoietic Cell Growth and Differentiation.

Anna Kalota, MS, Kistin Brennan, Connie L. Erickson-Miller, Gwenn Danet, PhD, Martin Carroll, M.D., Alan M. Gewirtz, M.D.

Blood (2004) 104 (11): 2913.

https://doi.org/10.1182/blood.V104.11.2913.2913

Published: 2004

Journal Articles

SB 497115-GR, a Low Molecular Weight TPOR Agonist, Does Not Induce Platelet Activation or Enhance Agonist-Induced Platelet Aggregation in Vitro.

Joseph Erhardt, PhD, Connie L. Erickson-Miller, PhD, Peter Tapley, PhD

Blood (2004) 104 (11): 3888.

https://doi.org/10.1182/blood.V104.11.3888.3888

Published: 2004

Journal Articles

Cellular and molecular mechanisms of the bone marrow sparing effects of the glucose chloroethylnitrosourea chlorozotocin

P Byrne, K Tew, J Jemionek, T MacVittie, L Erickson, P Schein

Blood (1984) 63 (4): 759–767.

https://doi.org/10.1182/blood.V63.4.759.759

Published: 1984

NARROW

Investigating Effects of Cyclosporine on Eltrombopag Pharmacokinetics in Healthy Volunteers: A Phase 1 Crossover, Drug-Drug Interaction Study

Eltrombopag, but Not Romiplostim or Thrombopoietin, Inhibits Growth of Thrombopoietin Receptor Positive and Negative Human Leukemia Cell Lines

Hepatic HIF-2 regulates erythropoietic responses to hypoxia in renal anemia

Eltrombopag Decreases Proliferation of Ovarian, Lung and Breast Tumor Cell Lines.

In-Vitro Effect of the Small Molecule Thrombopoietin (TPO) Receptor Agonist Eltrombopag in Chronic Lymphocytic Leukemia (CLL).

Effect of the nonpeptide thrombopoietin receptor agonist Eltrombopag on bone marrow cells from patients with acute myeloid leukemia and myelodysplastic syndrome

Low or Undetectable Levels of Thrombopoietin Receptor (Tpo-R; c-mpl) Expression on Tumor Cell Lines and Primary Tumors Compared with Epo-R, ErbB2, and IGF-1R

DYRK3 Encodes an Inhibitor of Erythroid Differentiation and Is Expressed at High Levels in Patients with Anemia.

The Characterization of DYRK3 mRNA and the Utility of DYRK3 Inhibitors in a Carboplatin/Radiation Mouse Model of Anemia.

GSK626616: A DYRK3 Inhibitor as a Potential New Therapy for the Treatment of Anemia.

Eltrombopag Decreases Proliferation of Human Leukemia and Lymphoma Cell Lines In Vitro.

Phase 1 clinical study of eltrombopag, an oral, nonpeptide thrombopoietin receptor agonist

Species Specificity and Receptor Domain Interaction of a Small Molecule TPO Receptor Agonist.

Discovery of SB-497115, a Small-Molecule Thrombopoietin (TPO) Receptor Agonist for the Treatment of Thrombocytopenia.

Effects of SB559457, a Novel Small Molecule Thrombopoietin Receptor (TpoR) Agonist, on Human Hematopoietic Cell Growth and Differentiation.

SB 497115-GR, a Low Molecular Weight TPOR Agonist, Does Not Induce Platelet Activation or Enhance Agonist-Induced Platelet Aggregation in Vitro.

Cellular and molecular mechanisms of the bone marrow sparing effects of the glucose chloroethylnitrosourea chlorozotocin

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only